Company: BSX
Filing Date: 2025-08-01
Form Type: 10-Q
Source: 0000885725-25-000041
Chunk: 83

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-08-01
Form: 10-Q
Item: Part I, Item 1
Chunk 83
---
 GAAP and should not be considered in isolation from, or as a replacement for, the most directly comparable GAAP measure. Refer to Additional Information for a discussion of management’s use of these non-GAAP financial measures. 

41

The following is a reconciliation of our results of operations prepared in accordance with GAAP to those adjusted results considered by management. Refer to Quarterly Results and Business Overview and Additional Information for a discussion of these reconciling items:

Six Months Ended June 30, 2025(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Net Income (Loss) Attributable to Noncontrolling InterestsNet Income (Loss) Attributable to Boston Scientific Common StockholdersImpact per ShareReported$1,746 $279 $1,467 $(4)$1,471 $0.98 Non-GAAP adjustments:Amortization expense444 62 383 4 378 0.25 Goodwill and other intangible asset impairment charges46 8 37 — 37 0.02 Acquisition/divestiture-related net charges (credits)57 (4)61 — 61 0.04 Restructuring and restructuring-related net charges (credits)210 26 184 — 184 0.12 Investment portfolio net losses (gains) and impairments6 2 5 — 5 0.00 EU MDR implementation costs23 3 19 — 19 0.01 Deferred tax expenses (benefits)— (91)91 — 91 0.06 Discrete tax items— (0)0 — 0 0.00 Adjusted$2,533 $284 $2,249 $1 $2,248 $1.51 

Six Months Ended June 30, 2024(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Net Income (Loss) Attributable to Noncontrolling InterestsNet Income (Loss) Attributable to Boston Scientific Common StockholdersImpact per ShareReported$1,028 $213 $815 $(4)$819 $0.55 Non-GAAP adjustments:Amortization expense427 58 369 4 364 0.25 Goodwill and